[Form 4] Avidity Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Avidity Biosciences insider Steven George executed transactions under a previously adopted Rule 10b5-1 plan, reducing his direct common stock holdings. On 08/13/2025 he acquired 1,542 shares via option exercise at a $6.57 exercise price and simultaneously sold 1,542 shares at $46.66 per share. After the transactions his direct beneficial ownership declined from 40,409 to 38,867 shares. The option that was exercised was granted on 09/11/2023 and vests monthly in equal installments, becoming fully exercisable on 09/11/2027. The 10b5-1 plan was adopted on 06/12/2024.

Positive

• Transaction executed under a disclosed Rule 10b5-1 plan, adopted 06/12/2024, which provides a documented trading framework
• Full disclosure of option grant and vesting schedule (grant 09/11/2023; vests monthly; fully exercisable 09/11/2027)

Negative

• Direct beneficial ownership decreased from 40,409 to 38,867 shares after the reported transactions
• Insider sold 1,542 shares on 08/13/2025, which may be viewed negatively by some investors despite being under a 10b5-1 plan

Insights

Corporate Governance Expert

TL;DR: Officer used a Rule 10b5-1 plan to sell shares after exercising vested option tranche; disclosure is consistent with standard governance practice.

The Form 4 shows a transparent, pre‑planned sale under a Rule 10b5-1 trading plan adopted 06/12/2024, which helps insulate the officer from insider-trading allegations. The filing discloses both the exercise of a tranche of options and the concurrent sale of the same number of shares, and reports the resulting change in direct beneficial ownership from 40,409 to 38,867 shares. Nothing in the filing indicates deviation from the plan or other governance concerns based on the disclosed facts.

Securities Analyst

TL;DR: The transaction is a routine option exercise and market sale under a 10b5-1 plan, producing a modest reduction in insider holdings.

The reporting shows exercise of 1,542 option shares (exercise price $6.57) and immediate sale of 1,542 common shares for $46.66 each on 08/13/2025. The option grant date (09/11/2023) and vesting schedule (monthly tranches ending 09/11/2027) are disclosed, allowing investors to track future potential exercises and sales tied to vesting. Based solely on disclosed items, this is a routine liquidity event rather than a material corporate development.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hughes Steven George

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

10578 SCIENCE CENTER DRIVE, SUITE 125

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		M(1)		1,542	A	$6.57	40,409	D
Common Stock	08/13/2025		S(1)		1,542	D	$46.66	38,867	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.57	08/13/2025		M(1)			1,542	(2)	09/10/2033	Common Stock	1,542	$0	50,875	D

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.

2. This option was granted on September 11, 2023 and vests in equal installments of 1,542 shares on each monthly anniversary of such grant date, until it is fully vested and exercisable on September 11, 2027.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Steven George report on Form 4 for Avidity Biosciences (RNA)?

The filing shows on 08/13/2025 Mr. George exercised 1,542 option shares at $6.57 and sold 1,542 common shares at $46.66, reducing his direct holdings to 38,867 shares.

Were the sales part of a Rule 10b5-1 plan in the RNA Form 4?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 06/12/2024.

What is the vesting schedule of the option exercised by Steven George?

The option was granted on 09/11/2023 and vests in equal monthly installments of 1,542 shares per month until fully vested and exercisable on 09/11/2027.

How many shares does Steven George own after the reported transactions?

Following the reported transactions his direct beneficial ownership is 38,867 shares.

What prices were involved in the transactions reported on the Form 4?

The option exercise price was $6.57 and the reported sale price per share was $46.66 on 08/13/2025.